| Literature DB >> 34337299 |
Yu Takeuchi1, Tsuyoshi Etoh2, Kosuke Suzuki2, Tetsuji Ohyama3, Takahiro Hiratsuka4, Tetsuya Ishio5, Mutsuhiro Kugimiya6, Toshifumi Matsumoto7, Seiichiro Kai8, Toshio Bandoh9, Kohei Shibata10, Kentaro Iwaki11, Kouichirou Tahara12, Yuji Shigemitsu13, Masafumi Inomata2.
Abstract
BACKGROUND: Laparoscopic surgical approaches, including total extraperitoneal repair (TEP), have been widely accepted for inguinal hernia repair in Japan. However, there are limited data regarding recurrence after TEP in Japan, given the limited versatility of this procedure. This study retrospectively evaluated the rates of hernia recurrence after TEP and open mesh repair at multiple Japanese centers.Entities:
Keywords: TEP; inguinal hernia; open mesh repair; recurrence rate
Year: 2021 PMID: 34337299 PMCID: PMC8316736 DOI: 10.1002/ags3.12443
Source DB: PubMed Journal: Ann Gastroenterol Surg ISSN: 2475-0328
FIGURE 1CONSORT flowchart
Baseline characteristics before and after propensity score matching
| All patients (n = 1647) | Propensity‐matched patients (n = 1076) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| TEP (n = 1011) | % | Open mesh repair (n = 636) | % | Absolute standardized difference | TEP (n = 538, %) | Open mesh repair (n = 538, %) | Absolute standardized difference | ||
| Sex | Male | 886 | 87.6 | 577 | 90.7 | ||||
| Female | 125 | 12.4 | 59 | 9.3 | 9.94 | 11.0 | 10.8 | 1.83 | |
| Age | mean ± SD | 66.9 ± 14.9 | 69.9 ± 12.5 | 21.9 | 68.8 | 69.5 | 5.46 | ||
| BMI | mean ± SD | 22.9 ± 2.9 | 22.8 ± 3.0 | 2.78 | 22.8 | 22.7 | 4.13 | ||
| Life history | Smoking | 314 | 31.1 | 182 | 28.6 | 3.53 | 32.8 | 34.4 | 3.11 |
| Comorbidity | Constipation | 106 | 10.5 | 70 | 11.0 | 1.68 | 10.8 | 10.6 | 2.40 |
| Pulmonary disorder | 61 | 6.0 | 74 | 11.6 | 19.8 | 10.8 | 10.8 | 0.60 | |
| Prostatectomy | 14 | 1.4 | 87 | 13.7 | 47.9 | 2.6 | 2.8 | 1.15 | |
| Anticoagulant | 189 | 18.7 | 129 | 20.3 | 4.01 | 19.5 | 19.6 | 1.40 | |
| Ascites | 8 | 0.8 | 15 | 2.4 | 12.6 | 1.5 | 1.9 | 2.89 | |
| Contralateral operation | 103 | 10.2 | 74 | 11.6 | 4.64 | 10.6 | 10.0 | 2.45 | |
| Location | Left | 419 | 41.4 | 270 | 42.5 | ||||
| Right | 592 | 58.6 | 366 | 57.5 | 2.04 | 58.6 | 57.4 | 2.63 | |
| Type | Lateral | 775 | 76.7 | 480 | 75.5 | 2.48 | 77.3 | 75.9 | 2.57 |
| Medial | 144 | 14.2 | 108 | 17.0 | 7.74 | 16.3 | 17.8 | 3.08 | |
| Femoral | 46 | 4.5 | 19 | 3.0 | 8.25 | 3.4 | 3.3 | 3.96 | |
| Other | 23 | 2.3 | 12 | 1.9 | 1.35 | 3.1 | 2.8 | 2.07 | |
| Missing | 20 | 2.0 | 14 | 2.2 | |||||
| Initial/Recurrence | Initial | 986 | 97.5 | 589 | 92.6 | ||||
| Recurrence | 25 | 2.5 | 47 | 7.4 | 22.8 | 4.6 | 5.2 | 2.18 | |
Notation of propensity‐matched patients is described in percent except age and BMI.
Surgical outcomes before and after propensity score matching
| All patients (n = 1647) | Propensity‐matched patients (n = 1076) | |||||
|---|---|---|---|---|---|---|
| TEP | Open mesh repair |
| TEP | Open mesh repair |
| |
| % (n = 1011) | % (n = 636) | % (n = 538) | % (n = 538) | |||
| Overall intraoperative morbidity | 0.3 | 0.5 | .682 | 0.28 | 0.34 | .884 |
| Bladder injury | 0 | 0 | ||||
| Spermatic cord injury | 0.3 | 0 | .288 | 0.28 | 0 | .321 |
| Intestinal injury | 0 | 0.5 | .054 | 0 | 0.34 | .205 |
| Overall postoperative morbidity | 5.9 | 6.9 | .474 | 6.2 | 7.3 | .497 |
| Hematoma | 1.7 | 2.2 | .461 | 1.8 | 2.6 | .443 |
| Seroma | 1.4 | 2.4 | .178 | 1.4 | 2.6 | .222 |
| Superficial SSI | 0.1 | 0.6 | .077 | 0.05 | 0.38 | .325 |
| Chronic pain | 1 | 0.9 | 1 | 0.95 | 0.71 | .708 |
| Other | 1.8 | 0.9 | .207 | 1.9 | 1.1 | .325 |
| Operating time (min), median (percentile range 10–90) | 70 (46–123) | 67 (38–126) | <.001 | 70.2 (46.2–126) | 65 (37‐124) | <.001 |
| Blood loss (mL), median (percentile range 10–90) | 0 (0–5) | 0 (0–20) | <.001 | 0 (0–5.1) | 0 (0‐20.4) | <.001 |
| Length of postoperative hospital stay (days), median (percentile range 10–90) | 5 (1–8) | 7 (3–11) | <.001 | 5 (1.8–8.0) | 6.4 (3.0‐11.5) | <.001 |
| Recurrence | 0.6 | 1.1 | .266 | 0.5 | 1.0 | .375 |
Recurrence rate in TEP/TAPP and open mesh repair
| Author | Year | Study design | n | Recurrence rate (%) |
| ||||
|---|---|---|---|---|---|---|---|---|---|
| TEP/TAPP | Open (Procedure) | TEP/TAPP | Open | ||||||
| Andersson B [ | 2003 | RCT | 81 | TEP | 87 | L | 2.6 | 0 | .23 |
| Douek M [ | 2003 | RCT | 122 | TAPP | 120 | 1.6 | 2.5 | NS | |
| Neumayer L [ | 2004 | RCT | 862 | TEP; 90%, TAPP; 10% | 834 | L | 10.1 | 4.9 | NS |
| Hallen M [ | 2008 | RCT | 73 | TEP | 81 | L | 4.3 | 5.1 | .37 |
| Pokorny H [ | 2008 | RCT | 129 | TEP; 36, TAPP; 93 | 69 | L | TEP; 5.9, TAPP; 4.7 | 0 | NS |
| Eklund AS [ | 2009 | RCT | 616 | TEP | 659 | L | 3.5 | 1.2 | .008 |
| Eker HH [ | 2012 | RCT | 235 | TEP | 222 | L | 4.9 | 8.1 | .1 |
| Miserez M [ | 2014 | Meta‐analysis | 1341 | TEP, TAPP | 1330 | L | 2.8 | 1.8 | .12 |
| The HerniaSurge Group [ | 2018 | Meta‐analysis | 1237 | TEP, TAPP | 1281 | L | TEP;2.4, TAPP; 1.3 | 1.2 | NS |
| Gutlic N [ | 2019 | RCT | 202 | TEP | 214 | L | 2.2 | 1 | .36 |
| Gavriilidis P [ | 2019 | Meta‐analysis | 2678 | TEP | 2790 | L | 6 | 4 | .005 |
| Present study | Retrospective (PSM) | 538 | TEP | 538 | L/MP/K/DK/PHS | 0.5 | 1 | .375 | |
DK, Direct Kugel; K, Kugel; L, Lichtenstein; MP, mesh‐plug; NS, not significant; NS, not significant; PHS, Prolene Hernia System; PSM, propensity score matched analysis; RCT, randomized controlled trial.